Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China
Everest Medicines Limited (HKG: 1952) has entered into an asset acquisition agreement with Corxel Pharmaceuticals...
Deals
Novartis Acquires SNV4818 from Synnovation – USD 3 Billion Deal for Pan‑Mutant PI3Kα Inhibitor in Breast Cancer
Novartis AG (NYSE: NVS) announced a definitive agreement to acquire SNV4818, a pan‑mutant‑selective PI3Kα inhibitor,...
Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36
Samsung Bioepis Co., Ltd. has expanded its strategic partnership with Sandoz AG (SWX: SDZ), entering...
GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities
GE HealthCare (NASDAQ: GEHC) announced completion of the acquisition of Intelerad, a leading medical imaging...
Leveragen Partners with Daiichi Sankyo – In Vivo Antibody Discovery Collaboration Targets Advanced Biologics
Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, announced a...
Medbanks Acquires Jianyi Tech for RMB 360 Million – Insurance-Tech Deal Strengthens Corporate Health Security Platform
Sipai Health Technology Co., Ltd. (HKG: 0314), operating as Medbanks, announced the acquisition of 100%...
Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder
Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751...
Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders
Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ:...
Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug
Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for...
Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets
Shanghai Ark Biopharmaceutical Co., Ltd. has submitted an initial public offering (IPO) filing to the...
Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform
Everest Medicines Limited (HKG: 1952) announced the signing of a letter of intent to acquire...
Kintor Pharma Partners with Chicmax to Accelerate KT‑939 Commercialization – Active Cosmetic Ingredient Targets Whitening Market
Kintor Pharmaceutical Limited (HKG: 9939) has entered into a strategic partnership with Shanghai Shangmei Cosmetics...
PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma – Exclusive China Partnership for Weekly GLP‑1 Diabetes Drug
PegBio Co., Ltd. (HKG: 2565) has entered into a strategic cooperation agreement with Shanghai Tenry...
BeOne Innovation Center and Voyagers Capital Launch Fund – Early-Stage Drug Investment Vehicle Targets Guangzhou Biotech
The BeOne Innovation Center (BIC) and Voyagers Capital jointly announced the establishment of the “BeOne...
Ab&B Bio-Tech Partners with Walvax for Overseas Push – First China-Approved Trivalent Subunit Influenza Vaccine Targets Global Markets
Ab&B Bio-Tech Co., Ltd. (HKG: 2627) entered into a strategic partnership with Walvax Biotechnology Co.,...
Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market
Kintor Pharmaceutical Limited (HKG: 9939) entered into a strategic cooperation agreement with Zhejiang Fonow Medicine...
APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio
APC Group and Youcare Pharmaceutical Group (SHA: 688658) signed a strategic cooperation framework agreement establishing...
WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications
WuXi Biologics (HKG: 2269) announced a strategic cooperation agreement with Earendil Labs, the overseas subsidiary...
Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD
Everest Medicines (HKG: 1952) announced positive topline results from its Phase IIa study of VIS-101,...
Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market
Luye Pharma Group Limited (HKG: 2186) announced a strategic cooperation agreement with Sinopharm Group Co.,...